Estramustine
Hormone Therapy
DB01196
Approved Indication
For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate
4
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors.
Details
DrugBank ID
DB01196 ↗
Approval Date
1992-01-01
Molecular Weight
440.403 g/mol
Drug Class
Hormone Therapy
ATC Codes
L01XX11
Synonyms
Estramustina, Estramustine, Estramustinum
PubChem
CID: 259331 ↗
ChEMBL
CHEMBL1575 ↗
SMILES
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]
ADMET Profile
Computing properties…